Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL).

ABSTRACT:

Objectives

Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines. So far there had been no prospective health economic evaluation of its use.

Methods

Cost-utility analysis of the CEQUEL trial comparing quetiapine plus lamotrigine vs quetiapine monotherapy (and folic acid vs placebo in an add-on factorial design) for patients with bipolar depression (n = 201) from the health and social care perspective. Differences in costs together with quality-adjusted life years (QALYs) between the groups were assessed over 52 weeks using a regression-based approach.

Results

Health-related quality of life improved substantially for all randomization groups during follow-up with no significant diff

SUBMITTER: Simon J 

PROVIDER: S-EPMC6491973 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature